Showing results (211-220 of 274) with videos related to

Sort By:
Pageof 28
Food Additives and Contaminants|October 18, 2005
Functional barriers: properties and evaluationA Feigenbaum, P Dole, S Aucejo, et al.
Journal of Hepatology|October 15, 2015
Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiencyBenjamin L Farah, Dustin J Landau, Rohit A Sinha, et al.
Journal of Inherited Metabolic Disease|July 26, 2018
Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapyElizabeth D Brooks, Dustin J Landau, Jeffrey I Everitt, et al.
Blood|September 9, 2025
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, et al.
Clinical Biochemistry|September 25, 2016
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral bloodKazunori Murata, Samuel I McCash, Brittany Carroll, et al.
Leukemia|June 25, 2021
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosisAngela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, et al.
Human Gene Therapy|December 22, 2011
Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type IaAmanda Demaster, Xiaoyan Luo, Sarah Curtis, et al.
Human Molecular Genetics|September 27, 2018
Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type IaLauren R Waskowicz, Jin Zhou, Dustin J Landau, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient SurveyNadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
Pageof 28